We included 1963 Framingham Original and Offspring Cohort participants with available CMB data and follow-up information for mortality, after excluding participants with prevalent stroke, dementia, or other neurological conditions that could affect MRI measures ( Figure  I in the online-only Data Supplement). Details of sample selection, MRI protocol, and vascular risk factor definitions are presented in the online-only Data Supplement. The Institutional Review Board of Boston University Medical Center approved the study protocol, and informed consent was obtained from all subjects.
C erebral microbleeds (CMB) are subclinical markers of cerebral small vessel disease (CSVD) associated with stroke, dementia, and modifiable vascular risk factors.
1-3 CMB represent a common magnetic resonance imaging (MRI) marker of hemorrhage-prone CSVD, but are also associated with ischemic events. 4 CMB may reflect an aggregate measure of vascular disease burden, and their detection may portend higher risk of mortality. 5 We investigated the association between CMB and mortality in a large sample of neurologically healthy people dwelling in the community, accounting for vascular risk factors, preventive cardiovascular medication use, and ischemic brain MRI measures of CSVD.
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confidence intervals for all-cause, cardiovascular, and stroke-related mortality. 
Results
Among the 173 participants (8.9%) with CMB, 64% had single and 36% had multiple CMB. Participants with CMB were older, more likely to be men, had higher prevalence of vascular risk factors and previous cardiovascular disease, higher use of preventive medications, white matter hyperintensity volumes, and presence of covert brain infarcts (Table 1) . Over a mean (SD) period of 7.2 (2.6) years, 296 participants died of any cause, 60 died of cardiovascular disease, and 17 of stroke. Crude incident rates of all event types were higher among participants with CMB (Table I in the online-only Data Supplement).
Participants with any CMB had a modest increase in risk of all-cause mortality (hazards ratio, 1.39; 95% confidence interval, 1.03-1.88), but the associations were attenuated and no longer significant after adjustment for vascular risk factors (Table 2) . Similar hazard ratios were observed among participants with lobar CMB and deep/mixed CMB, though with imprecise and nonsignificant estimates. Results pertaining to cardiovascular mortality were limited by lower number of events in CMB subgroups. Participants with ≥2 CMBs had a higher risk of all-cause mortality after adjustment for age and sex (hazards ratio, 1.56; 95% confidence interval, 1.06-2.31), but the association was attenuated after adjusting for vascular risk factors (Table II in 
Discussion
In this prospective community-based study of participants free of neurological disease, detection of CMB was associated with a modest increase in all-cause mortality, but the association was not independent of vascular risk factors and use of preventive treatments.
Other studies have found that CMB are associated with increased risk of death among people with dementia 8 and stroke 9 and in a single community-based study. 10 CMB may reflect the deleterious effect of long-term exposure to vascular risk factors in the cerebral vasculature. Our observation that participants with CMB had higher burden of ischemic CSVD (ie, more covert brain infarcts and higher white matter hyperintensity volumes) supports this hypothesis. Further, prior studies suggest that CMB may be detectable before other organ involvement, such as kidney or heart. Thus, CMB detection may offer a window of opportunity for clinicians to act on modifiable risk factors to prevent mortality.
Among the strengths of our study are the large populationbased cohort design, careful ascertainment of cardiovascular risk and preventive medication use, and inclusion of brain MRI markers of ischemic brain injury, all factors that may impact our outcomes of interest. Clinical outcomes were ascertained using detailed review of all medical records. We included participants free of neurological disease, with a younger mean age than in prior studies. Brain MRI measurements were reliable and were obtained blinded to clinical and demographic characteristics.
We submit that our results are unlikely to be biased by selection of participants into the study because their selection was unrelated to the exposure or outcome. Misclassification of exposure is possible, related to underdetection of CMB compared with studies using higher magnetic resonance strength or more sensitive MRI protocols, but any misclassification would be nondifferential, most likely to underestimate true effects. Our analyses involving prespecified CMB subgroups are limited by the smaller sample and fewer 
